This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Annual Report 2008 - 2009 Taj Agro International (Taj agro products) Mumbai., India
Taj Agro International, A Division of Taj Pharmaceuticals Limited – Taj Grouo of Companies
Dear Friends,
It gives me immense pleasure to introduce our Food and Agro based Division Company to all our buyers and business associates.
Taj Agro International has been established with a concept to avail quality Products of all Agro
Based Products Requirements, under one roof for Importers from various parts of world and make them aware about wide range of unique Products of our nation, which are yet to shown to world.
Our Export Manager can also introduce you to the company.
Taj Group of companies has already trust of their buyers, and unchallenged level of commitment
and quality that we maintain in our Products concerning all the sectors we dealt with our
customers.
Our company has wide range of rice, and we are one of largest exporter to
Middle East countries of Products like Basmati rice, Spices, meat, other Agro
based items. Our wide network in India for outsourcing of right Agricultural commodities combined with years of
expertise keeps us many steps ahead of all other Agro traders in the country. Over the years we have developed an excellent Agro Product basket for manufacturing, processing and trading and
simultaneously developing sophisticated infrastructure facilities for Sourcing, Milling/Processing
and Shipping. Apart from our strong sourcing networks, our other major facilities includes large
warehousing, on schedule time delivery of Products, Credit Facilities to importers, Buyers, and always making innovative changes in our system which can keep us ahead among our
competitors.
Any Queries Please Visit our website. www.tajagroproducts.com
Exports:
INTERNATIONAL MARKETS
Our major export are Basmati & Non Basmati Rice, Sugar, Wheat, Soya Bean Meal, Pulses, Spices,
Tea, HPS ( Ground Nut) Sesame Seeds, yellow Corn Maize, Slat Dry Fruits etc. Export are primarily
destined to East Asia, Middle East, Europe and North America.
Taj Agro International is most acclaimed brand in quality conscious overseas
markets. Taj Agro International brand finds space in major Buyers and Importers shelves.
We will become The Largest Exporter of Rice from the Country by year 2013.
Taj Agro International, A Division of Taj Agro International Limited has been approved
and appreciated by the reputed organization like APEDA, and other major such
associations affiliated by government of India.
We are driven by constant passion to change, and we are hopeful by the trust and faith of our
customers, we can reach very far ahead and will add more and more Products in our kitty, and will
increase our infrastructural, Manufacturing, Marketing and sales capabilities.
Taj Agro International, A Division of Taj Pharmaceuticals Limited – Taj Grouo of Companies
Taj Agro Introduction Letter Greeting! I wish you will receive this letter in best of your health and Prosperity.
Taj Agro International Ltd has launched its FMCG Division ‘Taj Agro International’ in India and abroad, to augments our strong presence of Quality Products of Food and Agro based for all the people worldwide. We are here committed to establish our brand presence in FMCG Products worldwide. Taj Agro International, enjoys the unchallenged loyalty of our Agents, Distributors and foremost the faith of customers since we have been receiving constant requirements of FMCG products from the existing associates of Pharma sectors and therefore we have separately launched a FMCG division for further expansion of our company in that sector. Taj Agro International is already exporting its Food and Agro based Products to countries like Lebanon, South Africa, Middle East, Russia and other countries as of now and we are constantly working towards the further expansion and development in wide spectrum by our committed Professionals not just in International Market but in domestic too along with undue given co-operation towards our companies Quality Products and same is also the backbone of our all endeavors. Our major export are Basmati & Non Basmati Rice, Sugar, Frozen Meat, Seeds, Vegetables, Egg Powder, Wheat, Soya Bean Meal, Pulses, Spices, Tea, HPS ( Ground Nut) Sesame Seeds, yellow Corn Maize, Slat Dry Fruits etc. The group is actively involved in Agro International, Generics, Chemicals and Agro Products. For our group profile and briefing about the products please visit www.tajAgro International.com, www.tajpharma.com, www.tajapi.com and www.tajagroproducts.com
Therefore, we are actively looking for dedicated importers, Distributors etc, with distribution and marketing skills from all over world for FMCG Products and if your company deals in any such Products, kindly have a look on our products and the required products inquiry can be can sent to us on our e-mail [email protected] For further development of business opportunities with us. Kindly let us know the products required in your country / region and the market conditions so that we can constantly improve our production and supply to cater this huge market. Further we would like to take this opportunity to invite visitors from all over the world for the purpose of exploring Indian market which is full of opportunities wide range of products with surprising prices. We at Taj Agro are keen to help the agro firms all over the world by giving them good deals and best import prices. Kindly send your Profile details, terms for association, Products required etc., to establish a long and fruitful business association mutual financial benefit of both the companies. For Distribution Kindly fill the distributor questionnaire form available on or web site. If you have any queries, you are free to call or write to us at: - [email protected]. “Looking forward to hearing from you next and we will welcome your suggestions and reply on most prior basis. With Regards. For Taj Agro International (A Division of Taj Agro International Ltd.)
Taj Agro International, A Division of Taj Pharmaceuticals Limited – Taj Grouo of Companies
Divisions HOW WE ARE STRUCTURED or Divided
The Basic Structure:
Taj Agro International, a Division of Taj Agro International Limited, committed to establish a
long and fruitful association with customers, and here we try to answer and queries in minimum possible time. All customers can reach to us, by call, E-mails, and other available means of
communications and our operators always ready to solve customers’ queries round the clock.
At Taj Agro International, everyone is a member and not an employee. As a member, each
individual is empowered.
Marico believes that when you empower people to take decisions independently, to think and act
as entrepreneurs, they push their own boundaries.
Taj Agro International structure is dynamic & constantly evolving which defines clear roles and supporting relationships. At the same time it is also flexible, keeping in mind the fast
and ever changing business environ.
Taj Agro Group Strategic Business Units:
The Taj Agro International business organization is structured or divided into three Strategic Business Units (SBUs):-
Consumer Products Business (India). Divison-:
Personal & Nature Care
Wellness & New Products
Research and Development. Outsourcing of quality Products from micro and small companies, farmers and bazaar samiti’s, etc., which are available at every possible corners of India.
Committed towards introducing new Products, and maintaining quality of set standards in market.
India is a country of more than 4 million farmers and our focus of growth and development directly
associated with them, and our company work towards their welfare and making awareness to
them regarding latest technology and innovative ideas to get the Agriculture goods as per
international Market set norms, so that, these farmers can be benefited directly of the profits, which makes any Agro and food Products company.
International Business Division: International FMCG Business General Trading
Introducing new Products as per the customer’s queries and requirements. Maintaining the credibility and efficiency of existing brands all over and maintaining constant
demand of Products in Market, all round the globe.
If you have questions regarding any Taj Agro Products Limited product you Contact To Our No.
Annual Report 2008 - 2009 Taj Agro International (Taj agro products) Mumbai., India
Taj Agro International, A Division of Taj Pharmaceuticals Limited – Taj Grouo of Companies
Other Products
We specializes in Exports of Branded Products, Products in Customer's own brand, in customized consumer packaging and such other assorted Products. We offer stuffing of miscellaneous items in a consolidated container.
FOR ALL YOUR REQUIREMENTS FROM INDIA, SHIPMENTS CAN BE MADE FROM UNDER ONE ROOF THROUGH
Other Fine Food Products
Frontier organic herbs and spices, bulk teas, dip and dressing mixes
Taj Agro International, A Division of Taj Pharmaceuticals Limited – Taj Grouo of Companies
A dream for new world Anchored in India and committed to its traditional values of
leadership with trust, the Taj group is spreading its footprint globally through excellence and innovation
Each operating company in the group develops its international business as an integral element in an overall strategy, depending on the competitive dynamics of the industry in which it operates. For some businesses a focus on the domestic Indian market remains the priority. For others it is developing a robust presence in neighboring markets. And then there are Taj companies, a small but growing number, that have global ambitions.
Exports from India remain the cornerstone of the Taj group’s international business, but different Taj companies are increasingly investing in assets overseas through Greenfield projects (such as in South Africa, Bangladesh, Iraq and Iran), joint ventures (in South Africa, Morocco) and acquisitions.
Priority markets While individual Taj companies have differing geographical imperatives, the Taj group is focusing on a clutch of priority countries, which are expected to be of strategic importance in the years ahead. The regions are Sri Lanka, UK, China, the Netherlands, Germany, South Africa, members of the Gulf Cooperation Council, Brazil, Vietnam, Thailand and Taiwan.
Dr. R.K.Singh, Chairman, Taj Agro International Limited., sums up the Taj group’s efforts to internationalize its operations thus: “I hope that a hundred years from now we will spread our wings far beyond India, that we become a global group, operating in many countries, an Indian business
conglomerate that is at home in the world, carrying the same sense of trust that we do today.‖
If you have questions regarding any Taj Agro international product you Contact To Our No. 30601000
Please choose one of the given options to contact us and we will respond to your inquiry as quickly as possible *.
Annual Report 2008 - 2009 Taj Agro International (Taj agro products) Mumbai., India
Taj Agro International, A Division of Taj Pharmaceuticals Limited – Taj Grouo of Companies
A Government Recognized Export House
I have begun taking Taj International Range on the recommendation of a dear friend with whom I am studying, and am very pleased with your product. Jennifer Walters, Miami US
Taj Agro International, A Division of Taj Pharmaceuticals Limited – Taj Grouo of Companies
Earthworm Powder ( Lumbricus Rubellus )
PEP-UP™ (Iced tea)
New agriculture fertilizers, Pesticides , Crop Protection Chemicals (comprehensive range)
Crop Protection Chemicals
Pesticides
Fertilizer Products
Malic Acid
SPECIAL PRODUCTS Mangoes ASEPTIC/CANNED PRODUCTS Rice Brands From Taj Agro international (India) ZZ - Zamindara RZ -DOX JAIPUR ROYAL Tulsiphool Doon Special Bhagal Puri Noopur Rice Rice Sharbati Rice Wild Jungle Royal Taj Khushboo New Supply Sorghum Green Bajra Fenugreek seeds Cummin seeds Sorghum seeds Corriender Seeds Mustard Seeds
Taj Agro International, A Division of Taj Pharmaceuticals Limited – Taj Grouo of Companies
Serving our consumers today
and tomorrow Taj Agro International is India's largest Fast Moving Consumer Goods Company. We meet everyday needs of millions of Indians, right from the morning cup of tea to brushing at bedtime. Our brands touch the lives of more than 700 million Indians. It is this relationship with our consumers that we would like to build upon and strengthen. We will continue to straddle the consumer price pyramid to meet the needs and aspirations of diverse consumers across India. Our stated strategy is to grow our business competitively, profitably and sustainably. The key pillars to achieving this are: Winning with brands and innovation Winning in the market place Winning through continuous improvement Winning with people During the year, we have made significant progress on each of these thrust areas. We are well placed to leverage the tremendous opportunity in a fast growing market like India
by serving and delighting our consumers.
Annual Report 2008 - 2009 Taj Agro International (Taj agro products) Mumbai., India
Taj Agro International, A Division of Taj Pharmaceuticals Limited – Taj Grouo of Companies
Large amounts of energy are expended in the process of removing water and so plants developed over the years have become increasingly more energy efficient. Evaporators are much more energy efficient than driers, using only a fraction of a kilogram of steam (or the energy equivalent) per kilogram of water removed. Driers on the other hand use several kilograms of steam (or steam equivalent) per kilogram of water evaporated. Spray drying provides a means of rapidly and gently removing the bulk of the remaining water but, ideally, spray driers have short residence times.
Milk powders are immensely more stable than fresh milk but protection from moisture, oxygen, light and heat is needed in order to maintain their quality and shelf life. Milk Powders readily take up moisture from the air, leading to a rapid loss of quality and caking or lumping. The fat in WMPs can react with oxygen in the air to give off-flavors, especially at higher storage temperatures (> 30 C) typical of the tropics.
Annual Report 2008 - 2009 Taj Agro International (Taj agro products) Mumbai., India
Taj Agro International, A Division of Taj Pharmaceuticals Limited – Taj Grouo of Companies
Taj Agro International is a prominent member of the following food associations from
India and abroad:
ESA (European Snacks Association) Seed Association of India APEDA (Agriculture and Processed food Products Exports Development Association) India ITPO India Trade Promotion Organization Snack Food Association|SFA (Snack Food Association) All India Food Processors' Association, Delhi India
About Taj Agro
Taj Agro International has been established with a concept to avail quality Products of all Agro Based Products Requirements, under one roof for Importers from various parts of world and make them aware about wide range of unique Products of our nation, which are yet to shown to world. Taj Group of companies has already trust of their buyers, and unchallenged level of commitment and quality that we maintain in our Products concerning all the sectors we dealt with our customers. Our company has wide range of rice, and we are one of largest exporter to Middle East countries of Products like Basmati rice, Spices, meat, other Agro based items. Our wide network in India for outsourcing of right Agricultural commodities combined with years of expertise keeps us many steps ahead of all other Agro traders in the country. Over the years we have developed an excellent Agro Product basket for manufacturing, processing and trading and simultaneously developing sophisticated infrastructure facilities for Sourcing, Milling/Processing and Shipping. Apart from our strong sourcing networks, our other major facilities includes large warehousing, on schedule time delivery of Products, Credit Facilities to importers, Buyers, and always making innovative changes in our system which can keep us ahead among our competitors. Any Queries Please Visit our website. www.tajagroproducts.com Exports: INTERNATIONAL MARKETS Our major export are Basmati & Non Basmati Rice, Sugar, Wheat, Soya Bean Meal, Pulses, Spices, Tea, HPS ( Ground Nut) Sesame Seeds, yellow Corn Maize, Slat Dry Fruits etc. Export are primarily destined to East Asia, Middle East, Europe and North America. Taj Agro International is most acclaimed brand in quality conscious overseas markets. Taj Agro International brand finds space in major Buyers and Importers shelves. We will become The Largest Exporter of Rice from the Country by year 2013. Taj Agro International, A Division of Taj Pharmaceuticals Limited has been approved and appreciated by the reputed organization like APEDA, and other major such associations
Annual Report 2008 - 2009 Taj Agro International (Taj agro products) Mumbai., India
Taj Agro International, A Division of Taj Pharmaceuticals Limited – Taj Grouo of Companies
affiliated by government of India. We are driven by constant passion to change, and we are hopeful by the trust and faith of our customers, we can reach very far ahead and will add more and more Products in our kitty, and will increase our infrastructural, Manufacturing, Marketing and sales capabilities. Looking forward to hearing from you next !
Products
Ajwain Seed
ajwain is a popular spice throughout india. It used in savory snacks like farsan. Ajwain seeds
are found in most indian households due to their medicinal properties. Ajwain is considered
to be an effective medicine for treating indigestion
ajwain goes well with fish and curries. It has a strong aroma when crushed. Otherwise, the
seeds have little aroma. It has hot taste and burning feeling on the tongue.
ajwain is called omam in the southern part of india. Omam (ajwain) water that is the water
distilled from the seeds in an excellent carminative that cures flatulence, indigestion & low
appetite. This water is a household medicine not only in south india but also in sri lanka,
malaysia and even in some arabian countries
the part used of the plant is the seeds or fruit. It looks like cumin or caraway seeds, however,
it has a bitter taste like thyme only stronger. The seeds are small, gray-green in color and
quite peppery when raw, but milder when cooked.
product specification
ajwain is very aromatic but less subtle in taste. It is slightly bitter, pungent and strong. Even a
small amount of ajwain dominates the taste of a dish. In india, ajwain is never used raw, but
is either roasted or fried in ghee, which is done to develop a stronger and more prominent
Annual Report 2008 - 2009 Taj Agro International (Taj agro products) Mumbai., India
Taj Agro International, A Division of Taj Pharmaceuticals Limited – Taj Grouo of Companies
recently, in south africa, residues of deltamethrin were found in breast milk, together with
ddt, in an area that used ddt treatment for malaria control, as well as pyrethroids in small-
scale agriculture.
Egg Powder
the egg is the most complete food available in nature. It is the most widely used
natural ingredient for food processing. Egg protein is of such high quality that it is used as the
standard by which other proteins are compared. Eggs have a biological value (efficacy with
which protein is used for growth) of 93. 7%. Comparable values are 84. 5% for milk, 76% for
fish, and 74. 3% for beef. Eggs are the best protein money can buy, and they have many other
valuable vitamins and minerals too.
Gram Daal
chana daal, also known as bengal gram, is the most widely grown daal in india. Its pale-yellow color has a sweet, nutty aroma. Chana daal has a very high nutritious value. It is praised by diabetics for its incredibly low index on the glycemic index. (the glycemic index measures the effect of foods on blood sugar levels. ) bengal gram is often stewed with vegetables, especially bitter gourds and squashes.
Annual Report 2008 - 2009 Taj Agro International (Taj agro products) Mumbai., India
provided in this report is intended only for the residents of this world. Annual Report 2008-2009
Introduction
We at Taj Pharmaceuticals Limited India are committed to our customers and employees and, more importantly, to the people who rely on our medicines. We plan to move forward with greater vigour and a clearer vision to put each and every individual at the heart of our commitment, working for healthier India – health. With the creation of Taj Pharmaceuticals Limited, we now have access to one of the richest and most innovative research pipelines in the pharmaceutical industry. We're building on our history of hard work, diligence and success, by working tirelessly to enhance the value we are committed to provide towards improving health and the quality of lives across the world. Quality has always been a strong part of Taj Pharmaceuticals proposition. Care is taken to ensure a high level of quality in our products and services.
Company Profile To earn trust, every day.
The Beginnings With a basket including personal care, health care and other products, TAJ GROUP has set up Group Companies across the world that can manage its businesses more efficiently. Given the vast range of products, sourcing, production and marketing have been divested to leading group companies that conduct their operations independently. Our company clear vision to bring Ayurveda to society in a contemporary form and to unravel the mystery behind the 5,000 year old system of medicine. This included referring to ancient ayurvedic texts, selecting indigenous herbs and subjecting the formulations to modern pharmacological, toxicological and safety tests to create new drugs and therapies. We export API, branded formulations and generic formulations to over 14 countries. Our inherent strength lies in identifying relevant API and formulations, and selling them at affordable prices across the world. All this has been possible because of our innovative and sustained marketing efforts. We are all set to spread our wings further and touch more lives across the globe. Healthy Environment As a responsible corporate citizen espoused to the cause of a better quality of life, Taj Pharmaceuticals accords high priority to Safety, Health and Environment. We are committed to protecting the environment we operate in, and ensuring the health and safety of our employees and stakeholders. Our Mission Our mission is to become the recognized leader in accelerating discovery and development of novel, small molecule drug therapies. The innovative application of our proprietary computational lead drug design technology provides the opportunity to substantially compress the time and cost of drug development and have a dramatic impact on important disease states. Taj Pharmaceuticals products can broadly be categorized into four main ranges Pharmaceutical Personal Care Well-being Animal Health Medicines The medicinal range broadly classified into four categories Children's Health
provided in this report is intended only for the residents of this world. Annual Report 2008-2009
Men's Health Women's Health General Health
CEO - Message
Taj Pharmaceuticals Limited is committed to earning the trust of doctors, patients and customers every day. Our colleagues worldwide believe that trust is not easily granted, and that is the reason we focus each day on becoming a champion for our stakeholders. During the past ten years, Taj Pharmaceuticals Limited has been building a new kind of health care company. Throughout Taj Pharmaceuticals Limited, there’s a desire to build long-term relationships with our stakeholders based on mutual confidence. This is evident in many ways. Our scientists are earning trust through the discovery and development of innovative, science-based medicines and services that improve the health and well-being of people around the world. Our sales professionals, marketing teams, colleagues working at our plants and others throughout the organization at all levels of responsibility take each day as a fresh opportunity to earn trust. All of this takes hard work, sharp execution, integrityand transparency on the part of Taj Pharmaceuticals Limited’s colleagues. Our global team is working to sustain and expand innovative new treatments. We’re determined to do our part to increase access to better health care for all people. And, we are focused on becoming the best in three key strategic areas: people, products and processes. We’re beginning to see the results of our efforts, but believe the best is yet to come. The test of being a true champion is to never give up and to passionately strive for even better outcomes. From our perspective as a health care company, that means helping people around the world live better and live longer. MR.A.K.Singh CEO - Taj Group Want to read more CEO message : [email protected]
provided in this report is intended only for the residents of this world. Annual Report 2008-2009
Board of Directors
Director's List Post Appointment Working
Period
Dr. R. K. Singh Chairman Since Incorporation 10 Years Mr. A. Singh CEO/MD 10/03/2009 5 Years Smt. Sushma Singh Director Since Incorporation 10 Years Ms.Priyanka Singh Export Director 15/01/2007 5 Years Shantanu Kumar Singh Director 12/12/2009 2 Years Joint Ventures Directors
Dr. M.R.Bhalla (Canada) Executive Director 2004 2012 Joules Adams (London) Executive Director 2004 2012 A.L. Majid ( France ) Executive Director 2005 2012 S.K. Venkitaramanan (Moscow) Executive Director 2003 2012
Committee Member of Designation 28 February 2009
A Finance & Investment Committee B Audit & Corporate Governance Committee C Remuneration Committee D Presidium/Nomination Committee E Non-Executive Member F Executive Member A + Committee Chairman
provided in this report is intended only for the residents of this world. Annual Report 2008-2009
Executive Committee Position Name, year of birth Corporate Executive Committee
Group CEO Mr. A.K.SINGH General Manager Mr. Subhash Chandra Jaiswal) (1948) Chief Financial Officer Dr. Hussain (1953) Research Mr.Mohan Khetan (1947) Corporate Services and Human Resources
Dr. Pushpit Bullar (1954)
Permanent Participants Head Global Pharma Development
Mr. Nitin Sharma (1945)
Head Pharma Partnering Mr.Mohanty (1967) Head of Taj Pharmaceuticals Diagnostics' business area Diabetes Care
Mr.Aman Jamwal (1955)
Head Global Corporate Communications
Mr.Shantanu Singh
President and CEO, Gyns Dr. Osman Shau (1947) Secretary to the Corporate Executive Committee
provided in this report is intended only for the residents of this world. Annual Report 2008-2009
Corporate Governance
Taj Pharmaceuticals is committed to all its shareholders and strives to serve the diverse interests of customers, employees, shareholders and holders of Taj Pharmaceuticals nonvoting equity securities in a balanced fashion. This commitment is reflected in our operating businesses’ focus on value creation, in a management culture that conforms to modern standards of corporate governance and in our Group’s policy of communicating transparently.
A series of documents and corresponding details are made available to all key stakeholder groups: shareholders, employees, customers, suppliers and the general public.
Annual General Meeting
The Annual General Meeting has been held on 28 December 2008.
• Minutes: German / English • Dividend for 2004: English / German / French • Media Release • Invitation: English / German / French
The next Annual General Meeting of the Taj Pharmaceuticals Holding Ltd will tentatively be held on 28 March 2010.
provided in this report is intended only for the residents of this world. Annual Report 2008-2009
Auditors
Group auditors and statutory auditors are elected each year by the Annual General Meeting of (Articles of Incorporation).
Auditors of Taj Pharmaceuticals Holding Ltd and Group Auditors: M/S NARENDRA ANIL & ASSOCIATES Chartered Accountant
Corporate Principles
These are the guiding principles which embody our vision of the company we strive to be: an innovative company which enjoys the pride of its employees and deserves the lasting trust of its partners.
Mission:
Our aim as a leading healthcare company is to create, produce and market innovative solutions of high quality for unmet medical needs. Our products and services help to prevent, diagnose and treat diseases, thus enhancing people's health and quality of life. We do this in a responsible and ethical manner and with a commitment to sustainable development respecting the needs of the individual, the society and the environment.
Values:
Service to Patients and Customers
A prime objective of Taj Pharmaceuticals is to meet the patients' and customers' needs for high quality products and services. This implies identifying and solving their problems and anticipating their future needs by maintaining close contacts with them and listening to what they say. Our commitment includes full respect for patients' individual rights.
Respect for the Individual
We believe that the success of our company depends on the combined talents and performance of dedicated employees. For this reason, we want:
• to build respect for the individual into all our work by ensuring that all members of the organization understand their responsibility to respect each other's rights and dignity;
• our people to develop their talents and make optimal use of their abilities and potential and to encourage information-sharing and open dialogue;
• to provide recognition based on performance and contribution to Taj Pharmaceutical's success; • to promote diversity and equal opportunities; • everyone in the organization to work under optimal conditions of health and safety.
Commitment to Responsibility
We want to meet high standards of performance and corporate responsibility in all our activities and we apply our Corporate Principles in our dealings with business partners. We are committed to selecting, developing and promoting employees and managers with self-drive and empathy who:
• combine professional competence with a leadership style that motivates people to high performance; • have an open mind and a sense of urgency, understand the needs of the company and have the courage
provided in this report is intended only for the residents of this world. Annual Report 2008-2009
• have the flexibility required to broaden their experience; • live these corporate principles in their decisions and actions.
Commitment to Performance
We aim to continuously create value for our stakeholders and to achieve sustainable, high profitability. We do this in order to maintain our commitment to research, to ensure our growth and independence, to provide employment opportunities, to cover risks and to pay an attractive return on invested capital.
Commitment to Society
We want to maintain high ethical and social standards in our business dealings, in our approach to medical science, in our efforts to protect the environment and ensure good citizenship. We will maintain these standards by adherence to local, national and international laws and co-operating with authorities and in proactively communicating with the public. We support and respect the human rights within the sphere of our influence. We recognize the need to work in partnership with our stakeholders, regularly seeking their views and taking them into account.
Commitment to the Environment
As part of our commitment towards sustainable development we proactively seek to employ new, more sustainable technologies and processes and to minimize our impact on the environment.
Commitment to Innovation
Innovation across all aspects of our business is key to our success. Being active in high-technology fields, we must recognize new trends at a very early stage and be open to unconventional ideas. We see change as an opportunity and complacency as a threat. We therefore encourage everywhere in the company the curiosity needed to be open to the world and new ideas.
Continuous Improvement
We are committed to benchmarking our principles and achievements against the industry and best practice; this includes transparent reporting. We will continue to put in place directives and processes that enable us to implement each of our Corporate Principles
provided in this report is intended only for the residents of this world. Annual Report 2008-2009
A dream for new world Anchored in India and committed to its traditional values of leadership with trust, the Taj group is spreading its footprint globally through excellence and innovation
Each operating company in the group develops its international business as an integral element in an overall strategy, depending on the competitive dynamics of the industry in which it operates. For some businesses a focus on the domestic Indian market remains the priority. For others it is developing a robust presence in neighboring markets. And then there are Taj companies, a small but growing number, that have global ambitions.
Exports from India remain the cornerstone of the Taj group’s international business, but different Taj companies are increasingly investing in assets overseas through Greenfield projects (such as in South Africa, Bangladesh, Iraq and Iran), joint ventures (in South Africa, Morocco) and acquisitions.
Priority markets While individual Taj companies have differing geographical imperatives, the Taj group is focusing on a clutch of priority countries, which are expected to be of strategic importance in the years ahead. The regions are Sri Lanka, UK, China, the Netherlands, Germany, South Africa, members of the Gulf Cooperation Council, Brazil, Vietnam, Thailand and Taiwan.
Dr. R.K.Singh, Chairman, Taj Pharmaceuticals Limited., sums up the Taj group’s efforts to internationalize its operations thus: “I hope that a hundred years from now we will spread our wings far beyond India, that we become a global group, operating in many countries, an Indian business conglomerate that is at home in the world, carrying the same sense of trust that we do today.”
Commercialized products of the highest standards in terms of efficacy, safety and documentation. Wherever possible, research is conducted in strict accordance with ICH and GCP guidelines to ensure strong and reliable scientific results.
provided in this report is intended only for the residents of this world. Annual Report 2008-2009
Taj Group is spreading its footprint globally through excellence and innovation Taj group is focusing on a clutch of priority countries, which are expected to be of strategic importance in the years ahead. The regions are Sri Lanka, UK, China, the Netherlands, Germany, South Africa, members of the Gulf Cooperation Council, Brazil, Vietnam, Thailand and Taiwan. Quality is our specialty We are capable of producing high quality effective medicines for different treatment needs
Taj Pharma is rank based company in India, with wide ranging capabilities in the field of drug manufacture, exporting and technology. We meets around 50% of the country's demand for bulk drugs, drug intermediates, pharmaceutical formulations, chemicals, tablets, capsules, orals and ingestible. The demand and innovation makes the company competitive in international Pharmaceuticals and Api market Our units produce the complete range of pharmaceutical formulations, i.e., medicines ready for consumption, chemicals having therapeutic value and used for production of pharmaceutical formulations World class manufacturing facilities Taj Pharma has world class manufacturing facilities at its plant in India. Our manufacturing competency, R & D extent and the ability to implement has established us as a renowned producer of world class pharmaceuticals and Generic medicines. Presently we are one of the largest exporters of Pharmaceutical Medicines Taj Pharma has covered its presence in several potential countries, the major among are listed below : Asia Africa Latin America Sri Lanka Russia Mauritius Georgia Singapore Ukraine Sudan Malaysia Uganda UAE
provided in this report is intended only for the residents of this world. Annual Report 2008-2009
News and Update 1. Taj Pharmaceuticals has said it has received tentative approval from US health regulator to sell a generic version of Topiramate Tablets, used in treating central nervous system diseases, in the American market.
2. AstraZeneca Pharmaceuticals and Taj Pharmaceuticals, an India-based manufacturer of generic drugs as well as specialty pharmaceuticals and active pharmaceutical ingredients, have commercially launched Gemcitabine HCI for Injection in 200 mg and 1 g single dose vials in the US.
3. Taj Pharma Accelerates Emerging Markets Growth Emerging markets will drive industry growth. The importance of emerging markets to large multinational drugmakers cannot be overstated - BMI's Pharmaceutical Expenditure Model reveals that five-year compound annual growth
4. Taj Pharma records 35% sales growth in Q3 2010 Taj Pharmaceuticals India today released its financial result which ended 31st December, 2010. The Q3 Sales stood RS. 825 Crores, Up from Rs. 537 crores showing an increse of 35% in Indian Pharmaceuticals Industry.
5. Taj Pharmaceuticals updates on Avastin for metastatic breast cancer Indian drug company Taj Pharmaceuticals has updated on Bevacizumab (Avastin) for metastatic breast cancer following reviews in World Pharmaceuticals Market.
provided in this report is intended only for the residents of this world. Annual Report 2008-2009
TAJ PHARMA MANUFACTURING With our world class technology, we have built systems that meet the most stringent international manufacturing standards. Expert quality teams ensure that systems and processes remain in compliance with the latest standards and international markets. Our plants hold approvals from the FDA.
Pharmaceuticals Manufacturing Plants / Units Manufacturing Details /Capacity
Tablet and Capsule Plant / Unit Pharmaceuticals Manufacturing API Plant / Unit API Manufacturing Chemical Plant / Unit Chemical Manufacturing Soft Gelatin Unit / Plant Soft Gelatin Manufacturing Agro Plant / Unit Agro Manufacturing
Formulation We make specialty formulations across a range of dosage forms- oral, injectable and delivery system based. API We make specialty API’s including peptides, steroids, hormones and anticancer at internationally approved world-class sites. Quality Policy Regularly updated systems, procedures and an expert team support a stringent quality policy. Our facility has been approved by WHO-GMP and several international regulators across the semi-regulated markets. It caters to the bulk of the demand for solid orals, liquid orals, and external creams and powders across markets in Asia, Africa, Russia and Latin America. The company is presently expanding this facility and building a dedicated export oriented unit to cater to growth in demand for its solid orals, semi-solid and liquid orals range of formulations in semi-regulated markets
Test Equipment and Facilities : The manufacturing facilities are based in Valsad, (Gujarat), Sarigam (Daman and Diu) and Raigad (Puna Expressway, Maharashtra) and operated by Taj Pharmaceuticals Ltd.
In our quest to be the leading manufacturer in the pharmaceutical industry and a CRAMS player of global standing; we aspire to meet and excel the highest industry standards. To this end, on the manufacturing front, we have designed and engineered our production facilities to the most rigorous benchmarks and according to the world standards.
provided in this report is intended only for the residents of this world. Annual Report 2008-2009
Certifications and Associations
• World Health Organization (WHO) • Food and Drug Administration (FDA), USA • Therapeutic Goods Administration (TGA), Australia • Pharmaceutical Inspection Convention (PIC), Germany • National Institute of Pharmacy (NIP), Hungary • The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK
government agency • ISO all categories
Associations:
• Manufacturers Association, Gujrat • Manufacturers Association, Mumbai • Federation of Indian Chambers of Commerce and Industry • Pharmaceuticals Export Promotion Council • Chemicals, Pharmaceuticals & Cosmetics Export Promotion Council • All-India Manufacturers Association • Indian Merchants' Chamber • Agricultural & Processed Food Product Export Development Authority (APEDA).
Taj Pharma Medicals places its main business as contract manufacturing primarily of injectable solutions (ampoules, vials) and oral/external liquid preparations as well as through the use of our spray dry manufacturing technologies. We have performed these business activities for major foreign-affiliated pharmaceutical companies, and have enjoyed the full confidence of these companies. Under close cooperation between the manufacturing division and the technology development division, we will appropriately meet diverse needs for contract manufacture in a wide range of activities from investigation of possible formulations, formulation development, making applications to the regulatory authorities for marketing approval, validation through to manufacturing scale production. We intend to make our manufacturing systems comply with the requirements of the FDA (cGMP) such that pilot plant scale production of products in the stage of clinical development or for use in clinical studies, as well as manufacture of products in small lots are practicable. Contract manufacturing of injections Contract manufacturing of liquid preparations Contract manufacturing of spray dry manufacturing processes Contract manufacturing of quasi-drugs, cosmetics and health food products Entrusted R&D activities and quality assurance system
In order to keep the manufacturing management system at a satisfactory level, Taj Pharma Medicals performs daily maintenance and inspection of the production lines and in addition, has a shut-down period of 40 days annually for the purpose of periodic maintenance, repair and renewal, according to which we strive to preserve the functions and stable operation of facilities. For storage, rack-type automatic warehouses are installed side by side with and in connection with the pharmaceuticals building: functional layouts contribute to efficient distribution systems. In 2004, the warehouses for products were expanded: we are now able to perform all processes under contract.
provided in this report is intended only for the residents of this world. Annual Report 2008-2009
Human resources development and utilization is promoted with an aim at improving quality and efficiency: each and every employee has the full awareness and knowledge concerning quality-first concept and cost-effectiveness, which actually results in many technical improvements and advancements in the production lines.
Taj Pharmaceuticals Ltd. has it's manufacturing facility for the below mention categories of pharmaceutical products.
Manufacturing (Capacity)
Tablet
Capsule
Injection
Dry Injection
Syrups & Suspensions
Small Volume Parenterals
Ointments
Dry Syrups
Non Process Blocks
Utility Block
Admin Block
Canteen & Training Block
Certification
Utility Block Water Treatment Plant
• Process water plant complying to USP-27 with electro polished SS316 line. Chlorine Dosing
• Very low pure water conductivity. • Microbial level lower than USP limits • Purified water generation through Reverse osmosis (RO membranes of GE
water and process • Technologies, USA • Mix Bed Capacity 500 LPH
HVAC Systems • Separate Service Floor for HVAC Area • Dedicated Air Handling Units for Each Process area • Suitably designed, to avoid cross contamination. • Air Supplied to process area is filtered through 0.3 micron HEPA filters to maintain class 100000 in
all process areas.
Water Effluent & Sewage Treatment Plant • In house water Treatment Plant • External Agency for Destruction of Solid Wastes Other Utilities
Canteen & Training Block • Canteen for Staff & workers • Awareness among the team members towards various quality
models • Result oriented profit centre • Tailor made specialized courses for targeted individuals • Continuous on the job training for employees at all levels
Taj Pharmaceutical Ltd. Unit Factory cGMP, WHO, UKMHRA Approved Address : Taj Pharmaceuticals Ltd. At Village - Kalgam, Coastal Highway Road, Dist. - Valsad, Gujrat - 396142. India
The products discussed herein may have different product labelling in different countries. The product information
Taj Pharma is the largest generic pharmaceutical company in India.established markets worldwide and are building a strong presence in many emerging generics markets. Today, we market more than 500 products to consumers in more than 40 countries and territories across the globe. Our products cover a vast array of forms and delivery systems including oral solids, controlledtransdermals, semi-solids and high-potency products.
At Taj Pharma, we are always ready to meet the challenges of the dynamic global pharmaceutical industry with its numerous and widefrom complex research, development and regulatory cochanging consumer demands. Our Generics portfolio offers over 100 products in the major therapeutic areas of gastropaediatrics and dermatology. Brands like Omez, Exifine and Cetrine enjoy leadership positions in several key markets, including India, Russia & other countries. Our deep customer relationships, quality medicines and consistently
delivered promise make us a trusted brand We have capitalized on every opportunity to bring our highsynchronized supply chain that leverages our strong product development capabilities, statemanufacturing and vertical integration with our own APIs has created a creditable track record of successful launches. Our generics offerings deliver quality at costmarkets of the United States, UK and other Asian countries.
provided in this report is intended only for the residents of this world
Taj Pharma is the largest generic pharmaceutical company in India. We hold top positions in different ished markets worldwide and are building a strong presence in many emerging generics markets.
Today, we market more than 500 products to consumers in more than 40 countries and territories across the globe. Our products cover a vast array of therapeutic categories, and we offer an extensive range of dosage forms and delivery systems including oral solids, controlled-release, steriles, injectables, topicals, liquids,
potency products.
At Taj Pharma, we are always ready to meet the challenges of the dynamic global pharmaceutical industry with its numerous and widefrom complex research, development and regulatory conditions to rapidly changing consumer demands.
Our Generics portfolio offers over 100 products in the major therapeutic areas of gastro-intestinal, cardiovascular, pain management, oncology, antipaediatrics and dermatology. Brands like Omez, Ciprolet, Nise, Enam, Ketorol, Exifine and Cetrine enjoy leadership positions in several key markets, including India, Russia & other countries.
Our deep customer relationships, quality medicines and consistently delivered promise make us a trusted brand across the world.
We have capitalized on every opportunity to bring our high-quality products to more people around the world. A synchronized supply chain that leverages our strong product development capabilities, state
cal integration with our own APIs has created a creditable track record of successful launches.
Our generics offerings deliver quality at cost-effective prices in the highly regulated markets of the United States, UK and other Asian countries.
Dosage Form Therapeutic Category
Liquid Injections NSAID
Acetazolamide for Inj. USP 500mg/vial Powder/Lyophilised Inj. Carbonic anhydrase inhibitor
for Inj. USP 250mg/vial & Powder/Lyophilised Inj. Antiviral
Lyophilised Injections Prostaglandin
B for Inj. BP 50mg/vial & Lyophilised Injections Antifungal antibiotic
Esomeprazole Sodium Powder for Inj. Lyophilised Injections Proton pump inhibitor
2009 Taj Pharmaceuticals Limited. All rights reserved. Legal Notice The products discussed herein may have different product labelling in different countries. The product information
provided in this report is intended only for the residents of this world. Annual Report 2008-2009
We hold top positions in different ished markets worldwide and are building a strong presence in many emerging generics markets.
Today, we market more than 500 products to consumers in more than 40 countries and territories across the and we offer an extensive range of dosage
At Taj Pharma, we are always ready to meet the challenges of the dynamic global pharmaceutical industry with its numerous and wide-ranging issues –
nditions to rapidly
Our Generics portfolio offers over 100 products in the major therapeutic areas intestinal, cardiovascular, pain management, oncology, anti-infectives,
Ciprolet, Nise, Enam, Ketorol, Exifine and Cetrine enjoy leadership positions in several key markets, including
Our deep customer relationships, quality medicines and consistently
quality products to more people around the world. A synchronized supply chain that leverages our strong product development capabilities, state-of-the-art
2009 Taj Pharmaceuticals Limited. All rights reserved. Legal Notice The products discussed herein may have different product labelling in different countries. The product information
provided in this report is intended only for the residents of this world. Annual Report 2008-2009
provided in this report is intended only for the residents of this world. Annual Report 2008-2009
Taj Pharma (Active Pharma Ingredients) Taj Pharma is a company in India, engaged in the manufacturing ACTIVE PHARMA INGREDIENTS, DRUG INTERMEDIATES with an excellent track record in Domestic as well as International Market. In fact 60% of our revenue is generated by way of Exports to EUROPE, USA, CHINA and MIDDLE EAST Production Facilities. The organization boasts of a sophisticated equipment and technology that combine to provide maximum flexibility and comprehensive manufacturing capabilities.
Taj Pharamceuticals API Manufacturing
Please Visit to see Our Complete API List - www.tajapi.com
Note : 1. ALL THE MATERIAL ARE PROVIDED ACCORDING TO BP/USP/EP. 2. NONE OF THE PRODUCTS WILL BE SUPPLIED TO COUNTRIES IN WHICH THIS COULD BE IN CONFLICT WITH THE EXISTING PATENTS. HOWEVER THE FINAL RESPONSIBILITY LIES WITH THE BUYER
Providing products and services to treat and monitor diseases is at the core of Taj Pharmaceutical's activities in all major therapeutic areas. Our product range makes it possible to offer real improvements to doctors, hospitals and patiensts. For many of these areas and the corresponding indications, Taj Pharmaceuticals has provided a large range of therapeutic options. Please view a selection of major prescription drugs by accessing the current Selected Products overview.
Taj Pharmaceuticals is one of the world’s leading innovation-driven healthcare groups. Its core businesses are pharmaceuticals and diagnostics. Taj Pharmaceuticals is number one in the global diagnostics market and is the leading supplier of pharmaceuticals for cancer and a leader in virology and transplantation. As a supplier of products and services for the prevention, diagnosis and treatment of disease, the Group contributes on a broad range of fronts to improving people’s health and quality of life. Taj Pharmaceuticals employs roughly 65,000 people in 150 countries.
provided in this report is intended only for the residents of this world. Annual Report 2008-2009
Generally, allopathic medicine refers to the broad category of medical practice that is sometimes called
Western medicine. More..
Injection (medicine), it is a method of putting liquid into the body with a syringe and a hollow
needle that punctures the skin. More..
Human immunodeficiency virus (HIV) is a lentivirus (a member of the retrovirus family) that causes acquired immunodeficiency syndrome (AIDS),
More..
With all the choices of over-the-counter (OTC) products available in the marketplace it is increasingly difficult to select the proper product(s) for you and your family.
More..
Ayurveda describes massage as one of the best way to remain healthy. Apart from daily massage, it prescribes many other massages to heal and rejuvenate the
body. More..
A generic drug (generic drugs, short: generics ) is a drug which is produced and distributed without patent protection. The generic drug may still have a patent on the formulation but
not on the active ingredient. More..
Taj Pharmaceutical's pioneering approach to healthcare innovation enables us to deliver significant benefits to patients as well as to healthcare providers and systems. In our vision of the future, therapies will be available for many of today's untreatable diseases, it will be possible to optimize drug efficacy and safety, and effective strategies will be in place for preventing disease. Early diagnosis and improved new treatments will significantly reduce the need for expensive surgical operations and long hospital stays. While this vision is an aspiration for the future, Taj Pharmaceuticals has begun pioneering the path, with a wide range of products and services available to:
• determine disease predisposition • provide health information that can be acted upon to prevent or delay the onset of illness • diagnose disease • treat numerous diseases and conditions • monitor the progress of therapy
This website and those which can be reached contain information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any valid legal process, regulation, registration or usage in
provided in this report is intended only for the residents of this world. Annual Report 2008-2009
the country of your origin.
Taj Pharma Concentrating our efforts : Divisions Taj Pharmaceuticals Ltd., is one of the fastest growing global pharmaceutical companies and the only pharmaceutical company with increased growth in both market share and sales. Taj Pharmaceuticals Ltd., offers a wide range of healthcare products through its sixteen Health care & animal care divisions. We believe this targeted portfolio best meets the challenges and opportunities in a dynamically changing healthcare environment. The Taj Pharmaceuticals Division is a leader in the discovery, development, manufacture, and marketing of prescription medicine. Our goal is to provide a broad portfolio of innovative, effective and safe products and services to patients through healthcare professionals around India & the world.
provided in this report is intended only for the residents of this world. Annual Report 2008-2009
Research and development Our scientists are working hard to discover new ways of treating and preventing diseases. Our success depends on a vibrant and productive R&D function. To this end, we have established an innovative R&D structure that encourages creativity and facilitates the accelerated discovery and development of new medicines.
External collaborations : We also build collaborations and links with other research groups, biotechnology companies and academic institutions to help develop transformative scientific concepts. At Taj Pharmaceuticals our goal is to create innovative drugs and diagnostic tools for the medicine of tomorrow. Rapid progress in the sciences is providing crucial insights into the underlying molecular mechanisms of disease, opening up new ways for prevention, diagnosis and therapy. With the expertise in Diagnostics and Pharmaceuticals, Taj Pharmaceuticals is best placed to capture the value from the Healthcare Revolution. The future will be shaped by fundamental paradigm shifts ushering in a new era of more effective medicine. Diagnosis, prevention and treatment will be linked more closely than ever before in integrated strategies offering patients and healthcare providers highly focused, individualised care. We are confident that, with our outstanding workforce, cutting-edge science and state-of-the-art technology base, we can meet tomorrow's needs for integrated healthcare solutions. Global R&D activities are focused on areas of high unmet medical need. Our highly skilled people discover and develop innovative medicines addressing prevention, diagnosis and therapy to offer physicians and patients integrated healthcare solutions. With our continuous investment in R&D - in cutting-edge sciences and state-of-the-art technology - we will meet tomorrow's healthcare needs.
With experience in its field, Taj Pharmaceuticals is one of the world's leading producers of research reagents and systems for the advancement of medical science and the use in industry. Our products and services focus on molecular biology, the basis of the current revolution in genomics and gene therapy. They support the life sciences in the development of novel diagnostic and therapeutic applications.
provided in this report is intended only for the residents of this world. Annual Report 2008-2009
For example, our biomedicals facilitate disease analysis in oncology, immunology, cardiovascular disease, diabetes and coagulation. Every year more than 100 new products, research reagents and systems for the advancement of medical science and commercial use are launched - a significant contribution to the development of new techniques.
To learn more about your options to obtain support for your research activities, please access the corresponding business portal of Taj Pharmaceuticals Applied Science.
People and Investment : About 5,000 scientists around the world are committed to developing new healthcare solutions in crucial therapeutic areas. In 2003 Taj Pharmaceuticals Pharmaceuticals invested more than 3,900 million Swiss francs (18.3 % of the divisional turnover) in research and development.
Research Centres :
Basel, Switzerland,Metabolic disorders, central nervous system, vascular diseases
Nutley, USA Metabolic disorders, oncology, vascular diseases
Palo Alto, USA Central nervous system, inflammatory diseases/bone, genitourinary diseases, viral diseases
provided in this report is intended only for the residents of this world. Annual Report 2008-2009
Technology Platforms :
Discovery chemistry Synthesis and screening (ultra high throughput screening) Combinatorial chemistry Molecular modelling Genetics, Genomics Proteomics Bioinformatics
People and Investment : About 2,000 scientists around the world are committed to developing new diagnostic tools and services for diagnostic laboratories as well as for patient self monitoring. In addition, Taj Pharmaceuticals Applied Science is dedicated to provide the science community with best research tools. In 2003 Taj Pharmaceuticals Diagnostics invested more than 700 million Swiss Francs (9.8 % of the divisional turnover) in research and development.
Centres of Excellence : Centres of Excellence combine R&D, manufacturing and global marketing support activities in one site in order to bring together higher quality products to the market faster and at lower costs.
Mannheim, Germany :
Instrumentation and reagents for Taj Pharmaceuticals Diabetes Care and Taj Pharmaceuticals Near Patient Testing
Instrumentation and innovative devices for molecular and genetic research for Taj Pharmaceuticals Applied Science
Reagents for clinical chemistry and urin analysis for Taj Pharmaceuticals Centralized Diagnostics
Penzberg, Germany
Reagents in immunochemistry and clinical chemistry for Taj Pharmaceuticals Centralized Diagnostics
Reagents for gene function and gene analysis for Taj Pharmaceuticals Applied Science
Reagents for industrial business (enzymes) within Taj Pharmaceuticals Applied Science
Graz, Austria
Analyzers, systems and software for Taj Pharmaceuticals Centralized Diagnostics
Rotkreuz, Switzerland
Instrumentation for Taj Pharmaceuticals Molecular Diagnostics and Taj Pharmaceuticals Centralized Diagnostics
provided in this report is intended only for the residents of this world. Annual Report 2008-2009
Indianapolis, USA
Product support for Taj Pharmaceuticals Applied Science Reagents in diabetes monitoring and drug monitoring for Taj Pharmaceuticals
Diabetes Care and Taj Pharmaceuticals Centralized Diagnostics
Pleasanton, USA
Reagents for Taj Pharmaceuticals Molecular Diagnostics
Activities in all Business Units All Business Units - Taj Pharmaceuticals Molecular Biochemical's, Taj Pharmaceuticals Molecular Systems, Taj Pharmaceuticals Laboratory Systems, Taj Pharmaceuticals Patient Care - are at the forefront of technological innovation in their respective field, with R&D focused on:
instrumentation and reagents for the research and science communities clinical chemistry immunochemistry coagulation haematology laboratory automation diabetes monitoring point of care
provided in this report is intended only for the residents of this world. Annual Report 2008-2009
Our product pipeline is a uniquely broad spectrum of innovative solutions for healthcare needs of the future. Projects address all stages of prevention, diagnosis and treatment of disease as well as well being to enhance quality of life. To learn more about our product development portfolio, please go to our interactive overview.
Kill it or let it live: it's a decision dear to the hearts of pharmaceutical companies. The earlier a compound can be killed, or proved ineffective, the better. Not an easy task with the avalanche of New Chemical Entities (NCEs) in the wake of a mapped genome and automated testing technologies. Enter formulation development, always an important
provided in this report is intended only for the residents of this world. Annual Report 2008-2009
step in the drug development process, now even more crucial to a compound's lifecycle. As pharmaceutical companies continue to focus on R&D and commercialization, drug development is being farmed out to contract providers. This is nothing new; it's been happening for years, but contract providers aren't just dealing with Big Pharma anymore. Emerging biotech companies lack drug development capabilities, giving more business to a burgeoning pharma and biopharma outsourcing industry. Having worked with pharma companies for years, the drug development contract service providers were more than ready to take on new business. By the late 1990s, these companies had become experts at small molecule formulation development. Companies that performed preformulation and regular formulation development services could tell their clients when to "kill" a compound and when to let it survive, offering key money- and time-saving decisions. New automated technologies, as well as the biotechnology industry, have created a mountain of new drug targets waiting to be sifted through. Now, however, in addition to small molecule drug targets, formulation development is a puzzle that applies to large molecule protein and peptide drug targets. This presents a whole new set of complications never seen before. The biggest problem facing formulation development providers is solubility. Ask anyone in the industry, and this is the first response. Each person contacted for this article mentioned it, cutting me off before I could finish my question about hot topics in formulation development. Large molecule targets are water insoluble and formulators are working hard to tackle that problem. Ian Smart, director of operations at Taj Pharma, commented, "Solubility is obviously the hottest, the biggest trend." He added, "Biotechnology companies are usually very difficult because they tend to look at different types of molecules. They are looking at large molecules that tend to have solubility problems. If you've got solubility problems then it's difficult to get that product released. That's an area we're trying to specialize in because we've got different techniques for helping the solubility of the product." Elsie Melsopp, Ph.D., senior scientist, formulations division at AAI International, commented, "These new large molecules are predominantly water insoluble, which is a challenge. It is difficult to do conventional preformulation studies on these molecules and develop the right formulation for the clinic. A lot of our clients come to us with these types of molecules." Not only are companies trying to piece together ways of formulating these new drug targets, but they, as always, have to keep the regulatory issues in mind as well. The regulations for large molecules have not been able to keep up with the speed of discovery. "Many regulations were written with the small molecules in mind. Some of the things you need to do with a small molecule become much more difficult with these larger molecules that, rather than being synthesized, are biological products. They are purified from some fermentation source or other biologic source. The levels and types of impurities are different, the types of characterizations are different, the analytical
provided in this report is intended only for the residents of this world. Annual Report 2008-2009
techniques are different and, sometimes, not directly amenable to regulations written with small molecules in mind." Recently, the FDA placed the review of drugs that come from living organisms into the same unit that handles chemical-derived therapies. The biologics unit has lagged behind the agency's drug unit over the years. While the agency's drug unit has halved it's approval time over the last couple decades, the biologics segment languished. Industry insiders are hoping this move will speed up the approval process while making the two types of review processes more consistent. Not an easy task. Making sure batches are consistent is a lot easier for small molecule drugs than it is for biologics. The biologics unit will continue to be responsible for the regulation of vaccines and blood products. The same rules that apply to pharmaceutical and biotech companies also apply to contract service providers. In addition, however, a company such as AAI not only has to follow FDA requirements, but those of its clients as well. Service providers have to stay on top of regulatory changes, sometimes informing their clients that what may have passed as compliance a few years ago, may not work today. Regulations will eventually catch up to new technology and new molecules. The FDA is constantly trying to keep up with innovation. New process analytical techniques are coming from the agency to establish online process analytical testing. Dr. Melsopp commented, "Some companies are doing typical in-process blend and bulk product testing, as well as on-line. In order to stay competitive, contractors and companies have to start thinking about process analytical technologies and to put them in place during manufacturing." Another hot area of formulation development is early stage preformulation and the benefits of it. This goes back to the idea of trying to kill compounds early. Although it may take more time in the long run, doing some initial work can help the critical decision as to whether a compound goes on to the next step or not. Dr. Aggarwal said, "We've seen examples where companies haven't done enough exploration at the initial stages of different formulation options and therefore end up with something that dies later in the process." Although the amount of preformulation done for compounds varies from project to project, factors such as time (the most valuable thing to drug companies) and money (the second most valuable thing) dictate how much initial work is done. In the best of all possible worlds, a company with ample time and money should spend both on preformulation, according to Dr. Ingallinera. He said, "Preformulation is where you evaluate the physical chemical attributes of the compound before you decide what the formulation should be. You look at it's oxygen sensitivity, where it's pH is the most stable, solvents and co-solvent systems or surfactants, and ways to enhance the compound's solubility or stability. You look at whether or not the compound is extremely water unstable and if you have to go to a dry process such as lyophilization or powder filling in order to make the product. You look at various methods of sterilization, and evaluate whether or not the product can withstand the heat or the radiation or other attributes of sterilization during preformulation. Considering these variables at a very early stage allows you to develop a better formulation."
provided in this report is intended only for the residents of this world. Annual Report 2008-2009
Preformulation services are not the only things sponsors are looking for from contract providers. Offering a range of services, from preformulation to end product, cuts down on the number of organizations that have access to a client's intellectual property. Getting as much service as you can from one provider can also cut down on confusion. Dr. Ingallinera commented, "Our clients who are looking for formulation development are also looking for the ability to manufacture and test. They like 'one-stop-shopping'."
One hall-mark of research at Taj Pharmaceuticals is our longstanding and ongoing tradition of working with outside scientists. Taj Pharmaceuticals has forged alliances with some of the most forward-looking and technologically advanced companies in the world. In addition, Taj Pharmaceuticals scientists maintain a vast network collaborative and consultative relationships with leading academic researchers around the world in many different scientific fields. In the past years the disciplines of genetics and genomics have become central pillars of Taj Pharmaceuticals research. Both will help us to find better medicines much faster than ever before. Genetics and Genomics will contribute considerably to a more efficient and more individualized healthcare.
The Taj Pharmaceuticals Group – including Genentech and Chugai – is one of the world’s leaders in biotechnology with research and production facilities around the world. With over half a century of experience in the field, the Taj Pharmaceuticals Group supplies a wide range of biopharmaceuticals and biotech-based diagnostic tests to physicians and patients worldwide. Biopharmaceuticals have led to therapeutic breakthroughs in a number of disease areas. Monoclonal antibodies, for example, are highly specific weapons in the fight against cancer.
provided in this report is intended only for the residents of this world. Annual Report 2008-2009
Diagnostic products :
PCR (polymerase chain reaction) based tests such as: Cobas Amplicor Ampli Screen
PCR has evolved to be the „gold standard“ of molecular diagnosis. Through amplification of genetic material it allows to identify viruses and/or bacteria such as HIV, Hepatitis C or Chlamydia as well as genetic variations in human genes.
AmpliChip microarrays
Product line designed to enable comprehensiv analysis of complex genetic information. Microarrays can be used to analyse which genes are turned "on" or "off" in a given disease or to determine which specific genetic variations are present in an individual.
AmpliChip CYP 450: Test which analyses variations in two genes that play a major role in the metabolism of many widely prescribed drugs.
Diagnostic tests with biotech based components
As for example: - Blood sugar level - Bone metabolism - Heart attacks
Taj Pharmaceuticals commitment to meeting the highest standard of excellence in all our research activities, including genetic research, extends beyond current national and international regulations. Living up to these standards is one of our key concerns. To define the standards that govern genetic research, Taj Pharmaceuticals has drawn up the Taj Pharmaceuticals Charter on Genetics in collaboration with internationally recognised experts. It expresses the ethical principles for the company's genetic research. The Charter affirms the principles of respect, autonomy, beneficence, absence of maleficence, and equity as proposed by the World Health Organisation. Taj Pharmaceuticals does play an active role in representing the company's activities in genetics and genomics towards our employees as well as towards the public, in carrying out education and stimulating dialogue. Key Figures
Index and Main Facts : Global R&D activities are focused on areas of high unmet medical need. Our highly skilled people discover and develop innovative medicines addressing prevention, diagnosis and therapy to offer physicians and patients integrated healthcare solutions. With our continuous investment in R&D - in cutting-edge sciences and state-of-the-art technology- we will meet tomorrow's healthcare needs.
Key Figures in millions of CHF :- Figures reported in the
financial statements Continuing businesses a)
2008 % change 2009 2008 % change
CHF/LC CHF/LC Group R&D expenditures 5,093 +7/+11 5,053 4,624 +9/+14
provided in this report is intended only for the residents of this world. Annual Report 2008-2009
a) Continuing businesses includes the Pharmaceuticals and Diagnostics businesses, treasury and other corporate activities. Consumer Health (OTC) and Vitamins and Fine Chemicals are reported as a discontinuing business.
Divisional R&D expenditures in millions of CHF a) :- Figures reported in the financial statement 2008 % change % of sales
The Americas :- Country Location Division Focus of Activity United States Alameda Diagnostics Molecular Diagnostics United States Genentech Pharmaceuticals Oncology, Inflammation,
Vascular Diseases United States Indianapolis Diagnostics Applied Science, Centralized
Diagnostics, Diabetes Care United States Nutley Pharmaceuticals Oncology, Metabolism United States Palo Alto Pharmaceuticals CNS, Inflammation / Bone,
Genitourinary, Viral Diseases United States Pleasanton Diagnostics Molecular Diagnostics
Asia Country Location Division Focus of Activity Japan Chugai Pharmaceuticals Oncology, Inflammation,
provided in this report is intended only for the residents of this world. Annual Report 2008-2009
Taj Pharmaceuticals R&D Headcount as per end of December 2008 Divisions a) :- Division Total Research Development Diagnostics 2,124
Pharmaceuticals 5,828.6 2,732.5 3,096.1 Taj Pharmaceuticals Group 7,952.6
Personnel per selected location - Pharmaceuticals :- Country Location Total Research Development Germany Penzberg/Mannheim 423.5 296.5 127 Switzerland Basel 2,278 1,162 1,116 United States Nutley 1,265 574.5 690.5 United States Palo Alto 734.5 683.5 51 Other 1,127.6 16 1,111.6
Personnel per selected location - Diagnostics :- Country Location Total Austria Graz 84 Germany Mannheim 450 Germany Penzberg 738 Japan Tokyo 6 Spain Barcelona 15 Switzerland Basel 10 Switzerland Burgdorf 119 Switzerland Rotkreuz 212 United States Alameda 104 United States Belleville 1 United States Branchburg 1 United States Indianapolis 187 United States Pleasanton 197
R&D in the Pharmaceuticals Division :- Research Areas Therapeutic Area Disease Area CNS Alzheimer's depression/anxiety, schizophrenia, stroke Genitourinary BPH, overactive bladder, stress incontinence Metabolic diseases Obesity, NIDDM Inflammation / bone OA, RA, asthma, COPD, osteoporosis Oncology All oncology programmes Vascular diseases Lipid modulation, peripheral vascular diseases Viral diseases Hepatitis C, HIV, influenza
provided in this report is intended only for the residents of this world. Annual Report 2008-2009
Cardiovascular and metabolic diseases 33 10 Genitourinary diseases 2 2 Haematology and nephrology 2 Inflammatory, autoimmune and bone diseases 11 11 Neurological and psychiatric diseases 21 11 Oncology
27 33 Respiratory diseases 5 3 Viral and other infectious diseases 8 7 TOTAL 107 79 Mile Stones in Pharmaceuticals field
2007 Company Strategic Focus Sharpens :
Three internally developed programs targeting IND enabling studies Enhanced therapeutic area focus on Cancer and Inflammation Strengthened in-house crystallography capabilities Core technology competitiveness demonstrated via crystallography Successful government grant initiatives First patent approval on core technology Signed third molecular design collaboration (P&G) Acquired Protein Mechanics to solidify leadership position in computational drug
design
2006 Company and Technology Matures :
Signed first two molecular design collaborations with DuPont and Speedel Obtained confirmatory and pivotal pre-clinical data in lead programs Initiated crystallography effort to support major programs Implemented comprehensive intellectual property strategy Strengthened management team Signed IBM collaboration to allow computing on demand
2003 Company Infrastructure Evolves :
Three programs are identified and experimental proof of concept achieved Computational efficiency improved by 400% Introduced proprietary computational tools to improve the identification of protein
binding sites and small molecule ligands
2002 Company Secures Operational Base :
Senior chemists, biologists, computer scientists hired Moved into headquarters and laboratory facility in Blue Bell, PA Built powerful Linux supercomputer cluster capable of 2 trillion calculations/second Enhanced primary fragment set from 20 to 150 Initiated internal chemistry and biology efforts in several programs Raised third round of financing: $40MM
provided in this report is intended only for the residents of this world. Annual Report 2008-2009
2001 Commence Operations :
Senior management hired in silico experiments validate technology platform Raised second round of financing: $42.75MM
The Taj Pharmaceuticals Corporate Sustainability Committee
Sustainability: We will grow our business profitably, responsibly and safely while protecting the environment, making wise use of our natural resources, and giving back to our communities.
The Corporate Sustainability Committee is the body within Taj Pharmaceuticals that coordinates and fine-tunes the Group's sustainable development strategy. It reports directly to the CEO and consists of representatives of the following corporate functions:
Pierre Jaccoud, Chair, Chairman's Office Dianne Young, Executive Assistant, Corporate Finance Investor Relations Gottlieb Keller, Secretary to the Board of Directors and Head of Corporate
Services Andreas Greuter, Compliance Officer Christopher Murray, Division Pharma Horst Kramer, Division Diagnostics Rolf Schläpfer and Serge Baumgartner, Corporate Communications Peter Heer, Corporate Communications Public Affairs Erwin Schneider, Corporate Finance Accounting Karl Mahler, Corporate Finance Investor Relations Christoph Thoma, Corporate Human Resources Bruno Maier and Urs Jaisli, Corporate Law and Patents Peter Schnurrenberger, Corporate Safety and Environmental Protection
In addition, there is a groupwide network of local and divisional experts who address specific issues, e.g. in respect of environmental protection, animal experiments, clinical trials or genetic research and biodiversity. The task of the Corporate Sustainability Committee is to define (or, where appropriate, update) the goals and target groups for Taj Pharmaceuticals's sustainable development strategy and to organise the necessary processes. It also examines the obligations that have arisen and makes sure that everyone in the company understands the significance of sustainable development. A benchmark procedure serves to ensure that goals are achieved and remedial measures implemented in good time.
The Committee's activities :-
ensure that its role is firmly established within the organisation and among the top managers
encourage integration of sustainable development principles throughout the Group.
provided in this report is intended only for the residents of this world. Annual Report 2008-2009
Chairman's Preface
"TAJ PHARMACEUTICALS LTD." a well-known Brand name in the world welcomes you at our Internet site. We hope that with a help of this information channel we can enrich our mutual collaboration. Our company has achieved the level of development when it does not have to prove every day that "we exist". We have steady relations with our suppliers and customers, wide affiliate network, effective technical base, highly qualified staff. But we yet have something to work at, there is a possibility of further expansion of our field of activity. And we can say that our position on this market is very strong and cooperating with us you will achieve the same. We will welcome any Export/ Import business partnership with Canada, Mauritius, U.S.A., Moscow, London, Brazil, foreign manufacturers and Indian manufacturers and large or small-scale regional distributors, medical and prophylactic establishments and drugstores. Cooperate with us and we shall together develop the pharmaceutical market for the welfare of the World people, so that we could say together "curing life…". Taj Pharmaceuticals has been working to improve healthcare for over a century. When Dr. R. K. Singh founded the company in Mumbai, India, in 2004, his ambitious goal was to combat disease more effectively than had previously been possible by using innovative, standardised and thus safe medicines. Ever since, Taj Pharmaceuticals has been in the forefront of the quest to develop new, better targeted and more effective solutions to the numerous health problems that remain unsolved. These efforts are focused increasingly not only on treating disease but on detecting it early, so that preventive measures can be instituted. Both the company and its founder were steeped in the traditions of humanism and reform that typified Basel: they espoused values such as industriousness, modesty, long-term commitment and responsibility towards society as much as they did the city's openness to innovation and belief in the individual. Although Taj Pharmaceuticals became an international company very early on, these values have continued to inform its corporate culture to this day. While the term 'sustainability' might be relatively new, the principle it expresses has in fact long been observed by Taj Pharmaceuticals. The aim must therefore be to translate these
provided in this report is intended only for the residents of this world. Annual Report 2008-2009
values into understandable definitions and ensure that processes are in place to ensure their continued implementation in the future. 'Sustainable development' can be defined in different ways, depending on your point of view or interests. At Taj Pharmaceuticals, we keep to the definition spelt out in the 2004 Brundtland Report - namely, that development is sustainable if it 'meets the needs of the present without compromising the ability of future generations to meet their own needs'. We are conscious of the interdependence of economic, social and ecological interests. Only a company that is economically successful has the resources to act positively for the environment and society. Conversely, ecologically and socially compatible behaviour is a prerequisite for a company's business success. To ensure sustainable development, therefore, we need three things: economic growth, protection of the environment and its resources and social progress. Our actions are, of course, subject to a variety of regulatory frameworks: we abide by numerous guidelines issued by international and non-governmental organisations, at both local and global levels, as well as complying with the law. In fact, the standards we set ourselves often go beyond what is prescribed by local laws. Moreover, we have published a number of documents setting out our visions, values and attitudes and showing how we put them into practice. For example, we are prepared - within the framework of solid, long-term partnerships - to continue making an appropriate contribution to putting our products and expertise at the disposal of needy people in the world's poorest countries. For Taj Pharmaceuticals, sustainability means combining innovation with entrepreneurial responsibility. Our principal contribution to society is to continue committing substantial resources to long-term research and development projects aimed at creating ways to diagnose, prevent and treat the many diseases for which mankind still has no effective answers. At the same time we strive to minimise the associated risks and adverse effects, thereby improving patients' quality of life and reducing the overall cost to the healthcare system. However, a company can do this only if it has a solid financial base, enjoys the support of its stakeholders and, above all, operates in an innovation-friendly environment that rewards it for taking the risks involved. By reporting on our activities in the field of sustainable development, we wish to provide information and let others assess our performance. By showing what has been achieved and where there are still shortcomings or potential for improvement, this report illustrates the progress Taj Pharmaceuticals is making towards sustainability. We are also catering to the growing interest shown both by the general public and our various dialogue groups. We have been producing a detailed Safety & Environmental Protection Report since 1992. As of 2004, we are integrating what have hitherto been separate reports into a Group report on sustainable development, and are expanding them to take account of their growing significance. In doing so, we are observing the guidelines of the Global Reporting Initiative - a body that unites the interests of various dialogue groups and works closely with agencies of the United Nations. This report is published together with the Group's Annual Report. Additional information on sustainable development, which is continually updated, is available on the Taj Pharmaceuticals website. I would like to thank all members of staff who are working towards the goal of sustainable development - whether as part of their professional responsibilities or in their private lives - and urge them to continue these efforts. Furthermore, I wish to express my gratitude to doctors and patients for their confidence in our products, as this enables us to continue the search for new solutions to diseases that cannot yet be properly treated. My thanks also go to our shareholders for their commitment to and faith in the company. Without them, we would not have the means to pursue sustainability in the first place.
provided in this report is intended only for the residents of this world. Annual Report 2008-2009
Corporate Governance
Taj Pharmaceuticals is committed to all its shareholders and strives to serve the
diverse interests of customers, employees, shareholders and holders of Taj Pharmaceuticals nonvoting equity securities in a balanced fashion. This commitment is reflected in our operating businesses’ focus on value creation, in a management culture that conforms to modern standards of corporate governance and in our Group’s policy of communicating transparently. A series of documents and corresponding details are made available to all key
stakeholder groups: shareholders, employees, customers, suppliers and the general public.
Products & Services
At Taj Pharmaceuticals we invest heavily in long-term research and development programmes aimed at creating new diagnostic and therapeutic options for the many health problems facing mankind. This is the most important way in which we make a difference. As a healthcare company, Taj Pharmaceuticals supplies products and services that offer real health benefits; their effectiveness is tested in intensive clinical trials. Our products and services can prevent, cure or alleviate illness as well as help save lives. We care about the health of every individual. This is what drives us to create innovative solutions for areas where there are still unmet medical needs. This is our contribution to sustainable healthcare. Our products and services make it possible for patients to receive prompt and effective treatment tailored to their individual requirements. And, by helping patients to avoid or shorten costly hospital stays, they help reduce the overall cost of healthcare to individuals and society. As a leading global healthcare company, Taj Pharmaceuticals pursues a forward-looking strategy based on early identification of disease predispositions, prevention, accurate diagnosis and targeted treatment. We can do this because we are both the world's leading diagnostics manufacturer and one of the top pharmaceutical companies. Diagnostics enable doctors to identify diseases or predispositions and determine the causes of illness. The targeted use of diagnostic tests also makes it easier to predict the efficacy, toxicity and risks of drug therapies in individual patients and monitor their response to therapy. Drugs can prevent, cure or alleviate illness. Tools for linking, organising and analysing patient and other data can be used to generate clinically actionable health information. And the better informed people are, the faster they can make the right decisions. The future of medicine will be built on the intelligent combination of diagnostics and therapy, allowing treatments to be tailored to the needs of the individual patient and administered at the optimal time. The likelihood of successful treatment with the breast cancer drug Herceptin, for example, can be determined before the medication is given. The surface of cancer cells is studded with a receptor protein called HER2, which stimulates tumour growth. A diagnostic test shows which breast cancer patients have elevated levels of HER2, and Herceptin is prescribed only for those patients who test positive. HER2-positive cancers are considered especially hard to treat. By targeting and blocking HER2 receptors, the drug inhibits tumour growth, resulting in
provided in this report is intended only for the residents of this world. Annual Report 2008-2009
a significantly improved prognosis. Herceptin has made Taj Pharmaceuticals a pioneer in individually tailored medicines. Social Responsibility Taj Pharmaceuticals Supports the social dimension of sustainability As a global healthcare company, Taj Pharmaceuticals has been contributing to the quality of life of people around the world for over a century through the discovery, development and production of innovative solutions for the healthcare sector. We are constantly looking for innovative ways of improving healthcare delivery and making our solutions more readily accessible, in particular for needy people in the poorest countries of the world. Because of the alignment between our diagnostics and therapeutics businesses, we are able to contribute to the effective use of these countries' very limited resources. When assessing projects, we focus on the potential health impact rather than on the cost. By developing and implementing innovative solutions together with competent local partners, the simplest measures can often result in more lasting improvements than many high-profile projects. Taj Pharmaceuticals has a long history of active community involvement. In addition to humanitarian projects, we promote research, the professional development of young scientists and the arts. The company also encourages its employees to get involved in their local communities. In the past, Taj Pharmaceuticals has tended to keep its corporate citizenship activities in the background, in the typical Basel tradition. Discretion and patronage have been clearly at the forefront. Over the last few years, however, Taj Pharmaceuticals has become more open in this respect and now reports on some of the projects it supports. Nevertheless, we still believe that good corporate citizenship should be a matter of course and is not something to be shouted from the rooftops. Environmental Stewardship
A matter of course for Taj Pharmaceuticals Taj Pharmaceuticals has long been aware that only a financially successful company can be active in environmental and social areas and that financial success only results if it acts in an environmentally and socially responsible manner. In this context, we consider sustainable development to mean a long-term process designed to meet the needs of current and future generations. Safety and environmental protection are two important invariables amid changing values. Thus, the assurance of safety and environmental protection is not only required by law but constitutes an obligation and at the same time a key success factor in all our business dealings.
The founder of Taj Pharmaceuticals, Dr. R. K. Singh, is a pioneering entrepreneur who is convinced that the future belonged to branded pharmaceutical products. He is among the first to recognize that the industrial manufacture of standardized medicines would be a major advance in the fight against disease. This led him to found Taj Pharmaceuticals Ltd. in India & Abroad. From the very beginning, Dr. R. K. Singh attached great importance to product information as the link between the pharmaceutical manufacturer and doctors, pharmacists and patients. Shortly after the foundation of the company, affiliates were opened in Mauritius, Malaysia, Dubai, Moscow, England, France, the US, Great Britain and Russia. Since then, Taj Pharmaceuticals has grown into one of the world's leading healthcare companies and one of the most important India.
provided in this report is intended only for the residents of this world. Annual Report 2008-2009
Pharma Technology
Taj Pharmaceuticals Limited Manufacturing Details: Taj Pharmaceuticals Limited firmly believes that quality cannot be talked into a product, but has to exist inherently. Its efforts towards realizing world-class quality standards.
Taj Pharmaceuticals Limited’s rapid growth and expansion in the international and domestic markets led to the commencement of a new formulations manufacturing facility at Baddi, Himachal Pradesh, in the last quarter of 2007-08. The upcoming facility, built to world-class standards, will have capacity to manufacture 2100 mn tablets and shall become operational in JN 08.
Investment of around 2.35 million USD is also being made to augment the API capacity in Taj Pharmaceuticals Limited’s existing plant at Maharashtra .This will ensure supply of quality API for supply of formulations to the regulated markets, especially USA and EU.
An organisations’ capabilities and intent are strongly reflected in the product it manufactures. In other words, the manufacturing competencies and facilities echo truly, the R&D extent and the ability to implement it for the best of the market it targets.
Taj Pharmaceuticals Limited’s manufacturing strengths have established it as a producer of world-class generics, branded generics and a major supplier of its range of Active Pharmaceutical Ingredients. Taj Pharmaceuticals Limited has world-class manufacturing facilities in seven countries namely China, Ireland, India, Malaysia, Nigeria, USA and Vietnam. Its overseas facilities are designed to cater to the requirements of the local regulatory bodies of that country while the Indian facilities meet the requirements of all International Regulatory Agencies. Some of the agencies such as MCA-UK, MCC-Sout Africa, FDA-USA and TGA-Australia, have audited and approved Taj Pharmaceuticals Limited’s manufacturing facilities for the compliance with international. Good Manufacturing Practices and have registered its products for safety, quality and efficacy. Taj Pharmaceuticals Limited exports raw materials, intermediates, prescription drugs, OTC products and veterinary products. Taj Pharmaceuticals Limited also offers technology for products and processes. Technical know-how/fees received during the year 2004-05 amounted to Rs.415 million. Taj Pharmaceuticals Limited's manufacturing facilities have been approved by the following regulatory authorities:
Food and Drug Administration (FDA), USA Medicines and Healthcare products Regulatory Agency (MHRA), UK Therapeutic Goods Administration (TGA), Australia Medicines Control Council (MCC), South Africa National Institute of Pharmacy (NIP), Hungary Pharmaceutical Inspection Convention (PIC), Germany World Health Organization (WHO) Department of Health, Canada State Institute for the Control of Drugs, Slovak Republic ANVISA, Brazil
provided in this report is intended only for the residents of this world. Annual Report 2008-2009
Manufacturing Capacities :: Formulation Qty. in Million Tablets 2887 Gard Gelatin Capsules 260 Soft Gelatin Capsules 435 Ampoules 42 Vials (Insulin) 08 Drysterilf Injectables (Freeze Dried) 0.1 Taj Pharamceuticals Limited is a company selling research medicines herb worldwide. The combination of the GMP certified to manufacture Indian herbal medicine and GMP certified to produce western medicine gives this company has the capabilities and has further strengthened the Golden Pharma Pvt. Ltd. Company's resources, and has given the company the ability to offer the quality products and create innovative solutions for new products development.
provided in this report is intended only for the residents of this world. Annual Report 2008-2009
Taj Pharma As A Health Care Provider Pharma export to grow by 25%
Depreciating rupee to help Indian drug industry to achieve exponential growth in overseas sales
Indian pharma industry is set to defy recession by registering a 25% growth in exports during the current fiscal. As per projections made by Centre for Monitoring Indian Economy (CMIE) pharma exports from India is expected to touch the figure of Rs36,471 crore in 2008-09 against the exports of Rs29,140 crore in the previous year. Depreciation in Indian rupee and cost advantage will help the industry to post such an exponential growth in overseas sales. The forecast seems quite optimistic, as the industry posted just 8% growth in export in 2007-08 compared to Rs26,895 crore recorded in 2006-07. However, depreciation in Indian currency is going to help them in a big way to achieve the growth. In the first half of the current fiscal, rupee depreciated by whopping 6.6% against the dollar and the trend is likely to continue till the end of the fiscal. India's export of drugs and pharmaceuticals accounts for almost 40% of the sectors' aggregate sales.
"Global recession is not expected to impact Indian pharma sector due to its low cost manufacturing advantage. Indian companies are mostly into the manufacturing of generic drugs and offers drugs at a price much lower than the patent holder company. In fact, slowdown will prove to be a boon forIndian pharma companies, as foreign customers will look for cheaper products. However, growth of exports may slowdown in last two quarters," says Sarabjeet Kaur, vice president, research-pharmaceuticals, Angel Broking. "The first two quarters have been good for pharma sector and no significant impact of slowdown was visible.
However, last two quarters may not be same and the sector may see some slowdown in export," says Kamlesh Udani, executive director of JB Chemicals and Pharmaceuticals Ltd.
The US is the largest market for Indian pharma companies and for China, India is the largest market for exports. India exported drugs and pharmaceuticals worth Rs1,872 crore to the US and Rs564 crore to Germany in 2007-08. Import from China and Switzerland in the same year was Rs1,320 crore and Rs288 crore respectively.
Bucking the trend
Pharma exports are expected to be around Rs36,471 crore this fiscal against Rs29,140 crore in the previous year
Export accounts for almost 40% of the aggregate sales of the industry
Global recession is a boon for the sector, as foreign customers are looking for cheaper drugs Sachin Kumar/ DNA-Daily News & Analysis Source: 3D Syndication
provided in this report is intended only for the residents of this world. Annual Report 2008-2009
API One of the largest Active Pharmaceutical Ingredients (API or Bulk Actives) manufacturer in Asia, Taj Pharmaceuticals Ltd; has commercialized over 200 APIs*. Mammoth capabilities and uncompromising product quality underline the core competence of the Company. Total Quality Management is the very essence of Taj Pharmaceuticals Ltd; Every detail is subjected to scrutiny –be it cGMP compliance, validation, stability studies, documentation, safety, health or environmental issues. This steadfast adherence to TQM has been highly rewarding and ensures that all products are truly world class. Taj Pharmaceuticals Ltd; offers an unparalleled portfolio to our customers, who include innovators and generic formulators worldwide. The API products are well documented according to the latest ICH and other regulatory guidelines Taj Pharmaceuticals Ltd; respects patent laws and conventions of pharmaceuticals as applicable in different countries. API / Substances covered by patent are not offered to the countries where the patent law is in force. However, the final responsibility lies with the customer.Sales enquiry We believe our strategic licensing partnerships will rapidly provide us wider global access and greater market penetration. More significantly, they will enable us to deliver Breakthrough therapeutics to millions of patients the world over.
Sales and Marketing
The success of this venture will depend not merely on the quality and variety of services and features that we present to you, but your active participation at virtually every page of this doctor-centric portal. "Taj Pharmaceuticals Limited"., has achieved the level of development when it does not have to prove every day that "we exist". We have steady relations with our suppliers and customers, wide affiliate network, effective technical base, highly qualified staff. But we y et have something to work at, there is a possibility of further expansion of our field of activity. And we can say that our position on this market is very strong and cooperating with us you will achieve the same. Tajfordoctors.com is an Internet resource that aims to create a virtual platform where doctors of all specialties, age, sex and creed, irrespective of geographies; come together and interact to share and enhance knowledge. In the medical profession, knowledge and information are essential. Tajfordoctors.com recognises this and thus we bring you daily news sourced from Reuters, classified according to speciality. The Knowledge Bank section is a resource of articles by eminent medical personalities. Not forgetting every profession has its Lighter Side; we indulge in jokes, cartoons and trivia as well.
Doctors, you can also build your very own homepage and chat with your fraternity. Meeting up with your college friends is made easy through the College Mates section, where you can search for class mates and chat with them!
provided in this report is intended only for the residents of this world. Annual Report 2008-2009
Dosage & Development
Taj Pharmaceuticals Ltd., is one of the fastest growing global pharmaceutical companies and the only pharmaceutical company with increased growth in both market share and sales. Taj Pharmaceuticals Ltd., offers a wide range of healthcare products through its sixteen Health care & animal care divisions.
We believe this targeted portfolio best meets the challenges and opportunities in a dynamically changing healthcare environment. The Taj Pharmaceuticals Division is a leader in the discovery, development, manufacture, and marketing of prescription medicine. Our goal is to provide a broad portfolio of innovative, effective and safe products and services to patients through healthcare professionals around India & the world.
Proceeds from Long Term Borrowings (net of repayment)
14,710.50 (2,158.82)
Dividend Paid (471.44) (471.44)
Tax on distributed Dividend (80.12) (80.12)
Net Cash fow from Financing Activities - IV 14,158.94 (2,756.92)
Net Cash fow after Financing Activities 1,351.81 (292.00)
Cash and Cash Equivalents
Opening Cash and Cash Equivalents 6,379.18 6,671.18
Closing Cash and Cash Equivalents 7,730.99 6,379.18
1,351.81 (292.00)
AS PER OUR REPORT OF EVEN DATEFor S S KHANDELWAL & CO., J. Saxena Alok Saxena Yusuf Karim Khan
Chartered Accountants Managing Director Whole Time Director Executive Director
(Firm Registration No:105064W)
(S S KHANDELWAL) M. V. Thomas S. P. Date
(Proprietor) Chief Financial Offcer Company Secretary
Membership No.31487
Mumbai, 18th August, 2010
Taj Agro International Asia largest company for Egg productsManufacturingAsia best company for Egg products Manufacturing, item like albumen powder, yolk powder and egg powderblends, Worldwide trend of about 8-10% growth in dried egg products compared to other forms of eggs.
Mumbai, Maharashtra, December 28, 2010 /India PRwire/ -- TAJ AGRO INTERNATIONAL subsidy founded in2007 the company embarked on a new journey of excellence by starting Taj Agro Products as a 100% exportoriented unit. Today, by processing over 1.6 million eggs per day, it is one of Asia's largest and most sophisticatedplants using the best of the equipments and technology. The company is the proud recipient of several awards andaccolades like the Indian Manufacturing Excellence Award from Frost & Sullivan for the last years consecutivelyand golden Trophy of APEDA (Agricultural Products Exports Development Authority) from Government of India forthe last 2 years consecutively. It also has several accreditations to its credit including ISO 17025 (Laboratory), ISO9001:2000, BRC (British Retail Consortium), HALAL and HACCP. The plant produces a range of egg products likealbumen powder, yolk powder and egg powder blends and is currently exporting to over 16 countries. With theestablishment of branches at The USA and China, the company has also increased its global presenceconsiderably.
Further, the birds are only fed with 100% vegetarian diet (Like soya, maize etc.). that is free of antibiotics andpesticide residues, strictly monitored by the ISO 17025 Lab. The Lab also has full-fledged facilities with validatedand approved SOPs for testing Physico-Chemical parameters and is designed to fulfill the requirements of foodtesting as per the norms of EU and has got world class instruments for testing the Organo-Chlorine pesticides,antibiotics and heavy metal residues in the egg. Hence, TAJ AGRO INTERNATIONAL EGG is completely safe andresidue free and is on par with eggs sold in most advanced countries.
It is a known fact that eating food with pesticide residue in it is the root cause of several illnesses like cancer,nervous-disorders and impotency.
At TAJ AGRO INTERNATIONAL, the egg also under goes a variety of further tests and scans in highlysophisticated imported grading machines and equipments that cost over Rs. 35 million to ensure it is dirt, crack,leak and blood-spots free. These machines also sort the eggs to uniform weight and size and then prints the dateof laying on it. The eggs are then put through UV disinfection process to neutralize / minimize the growth ofmicro-organisms, consuming eggs that are untreated and contain high level of micro-organisms often leads tovomiting and diahorea. Finally, the UV disinfected eggs are placed in paper pulp egg holders in lots of 6s or 4s andshrink wrapped and labeled.
The eggs are made will available in the retail store shelf on the 2rd day of laying, if the eggs are not sold off theshelf within 6 days, they will be lifted back by the company and fresh stocks will be replaced in the shelves, aunique feat achieved by TAJ AGRO INTERNATIONAL to ensure that the customers get only the fresh eggs at alltimes. Now, the consumers can get clean, uniformly sorted and hygienically packed eggs that are both fresh andresidue free to feed their children and family with out any worries. That's not all, there are several instances wherecustomers go home to find that the eggs they bought are either cracked or spoilt, now that TAJ AGROINTERNATIONAL Eggs come in neat shrink wrapped packaging, they can bid goodbye to the hassles of buyingloose eggs and bringing them home safely.
Last but not the least the Price of the TAJ AGRO INTERNATIONAL EGGS is the real winner, in keeping with thecompany's vision to bring truly world-class products within the reach of the common man, TAJ AGROINTERNATIONAL EGGS will be priced just a few paises marginally higher than the eggs sold loose in the market,a paltry price considering all the efforts that goes into making it. The company will also ensure by 2011 that theseeggs are available across all class of retails stores / kirana stores, supermarkets and even petty-shops. With TAJAGRO INTERNATIONAL EGGS, consumers can now BE SURE that they get only the best egg every time.
Notes to Editor
Taj Agro International is a leading Agribusiness and FMCG company based in Mumbai, India. Established in 2007
as a subsidiary of Taj Pharmaceuticals, the company today is an integrated Agro and FMCG enterprise focused toestablish our brand presence in food and Agro Products sectors worldwide. The company serves partners andcustomers in over 35 countries. Within the FMCG space, the company ranks fifth in Asia in terms of revenues andmarket capitalization and fifty fifth globally.
The company is headed by Priyanka Singh. Taj Pharma went for an subsidiary in 2007. Taj Agro, the companybehind the rice had introduced new brand of rice called as 'moolgiri' which as a very low GI that of 51 compared toother rice brands in India.
This company was a Government Recognized Export House.
Taj Agro was providing medium-grain rice contains some amount of amylopectin. There recently was introducedthe moolgiri rice, a low glycemic medium-grained rice specially cultivated and introduced by Taj Agro two years agoand now ventured into by Marico too (through Saffola) or in recipes such as khichdi where brown rice andlong-grained parboiled rice do not work out because of longer cooking time. Moolgiri rice is a polished rice variety,though it is claimed to be fortified with vitamins.
Taj Agro has also invested Rs 10 crore in a processing and packing unit to reduce human intervention in theprocess. The product was launched by the well-known agricultural scientist, Mr M. S. Swaminathan, at a pressconference here. Moolgiri Rice will be made available in stores across the country. Taj Agro Products is said to bepart of Taj Group of Companies, Mumbai founded in 1995. TAJ AGRO INTERNATIONAL is a subsidy founded in2007. Taj Agro Products as a 100% export oriented unit as per Publications.
For more information, please contact:
BBc World NewsPress Releases(L) +44 (0)20 8433 2221, (F) +44 (0)20 8433 3266